Liver Cancer News and Research RSS Feed - Liver Cancer News and Research

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Researchers demonstrate direct connection between NOX proteins and liver fibrosis

Researchers demonstrate direct connection between NOX proteins and liver fibrosis

Researchers at the University of California, San Diego School of Medicine have demonstrated a direct connection between two signaling proteins and liver fibrosis, a scarring process underlying chronic liver disease, the 12th leading cause of death in the United States. [More]
World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that the World Health Organization's International Nonproprietary Name group has accepted the proposed generic name "piclidenoson" for its lead drug candidate, CF101. [More]
Study elucidates on global prevalence of chronic hepatitis B infections

Study elucidates on global prevalence of chronic hepatitis B infections

Hepatitis B infections are among the most common infectious diseases worldwide. The disease can become chronic, and is one of the most important causes of severe diseases such as liver cancer. In the scope of an international study funded by the World Health Organization, scientists from the Helmholtz Centre for Infection Research in Braunschweig determined how often the chronic infection occurs in different countries and how many people of the general population are affected. They noted strong differences between different countries. [More]
Researchers at Sydney’s Centenary Institute fight against hepatitis infection

Researchers at Sydney’s Centenary Institute fight against hepatitis infection

Today is World Hepatitis Day. 400 million people around the world are currently living with hepatitis B or C. Each year, we see around 1.4 million people die from viral hepatitis. Researchers at Sydney’s Centenary Institute are working hard to change this. [More]
Resistance training can help reduce liver fat levels in patients suffering from fatty liver disease

Resistance training can help reduce liver fat levels in patients suffering from fatty liver disease

Resistance training in the gym leads to a fall in liver fat levels. This is the finding of a new study held at the University of Haifa in cooperation with Tel Aviv Medical Center and Tel Aviv University. [More]
Study points to new treatment strategies for liver cancer

Study points to new treatment strategies for liver cancer

A new study by researchers at Sanford Burnham Prebys Medical Discovery Institute, the National Cancer Institute, and the Chulabhorn Research Institute has found that blocking the activity of a key immune receptor, the lymphotoxin-beta receptor (LTβR), reduces the progression of liver cancer. [More]
Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announced today that the U.S. Food and Drug Administration Office of Orphan Products Development has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma. [More]
Mayo Clinic researchers test Spheroid Reservoir Bioartificial Liver to treat patients with acute liver failure

Mayo Clinic researchers test Spheroid Reservoir Bioartificial Liver to treat patients with acute liver failure

Approximately 30,000-40,000 people die from liver disease each year, according to the American Liver Foundation. For people who experience acute liver failure, the only proven treatment has been liver transplantation. Researchers at Mayo Clinic have developed and are testing an alternative to liver transplantation called the Spheroid Reservoir Bioartificial Liver that can support healing and regeneration of the injured liver, and improve outcomes and reduce mortality rates for patients with acute liver failure — without requiring a transplant. [More]
NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

Nutrition Science Initiative has launched the first-ever randomized, controlled clinical trial to determine whether removing added sugars from the diet can halt or even reverse nonalcoholic fatty liver disease (NAFLD) in children. [More]
Researchers identify DPP9 enzyme that can regulate growth, movement of liver cancer cells

Researchers identify DPP9 enzyme that can regulate growth, movement of liver cancer cells

Researchers at the Centenary Institute in Sydney have uncovered new information about an enzyme called DPP9 that they believe to be a potential therapeutic target for limiting tumour growth and its ability to spread to and in the liver. [More]
FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST). [More]
Risk of hepatobiliary cancer, cardiovascular diseases later in life is higher in women with ICP

Risk of hepatobiliary cancer, cardiovascular diseases later in life is higher in women with ICP

In a new study of more than 125,000 pregnant women in Sweden, researchers found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition. [More]
dlDNA marks progression of HBV-related liver disease

dlDNA marks progression of HBV-related liver disease

The level of serum duplex-linear DNA increases markedly with liver disease progression and development of hepatocellular carcinoma in patients with chronic hepatitis B virus (HBV) infection, suggests research published in Gut. [More]
Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today announced a publication of data demonstrating that in a Phase Ib trial of Pexa-Vec, patients received multiple bi-weekly doses of its lead product Pexa-Vec, representing the first report of multiple intravenous administrations of an oncolytic vaccinia. [More]
Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study. [More]
AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

The American Association for the Study of Liver Diseases, in partnership with the Infectious Diseases Society of America and in collaboration with the International Antiviral Society-USA, created online Recommendations for Testing, Managing, and Treating Hepatitis C in 2014 to aid practitioners treating patients infected with hepatitis C virus (HCV). [More]
PD linked to increased cancer risk in Asian population

PD linked to increased cancer risk in Asian population

A Taiwanese population-based cohort study reports an increased risk of most cancers in patients with Parkinson’s disease, contrasting with findings in Western populations. [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
Study suggests that blood clots in abdominal vein could be an indicator of undiagnosed cancer

Study suggests that blood clots in abdominal vein could be an indicator of undiagnosed cancer

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), concludes that a blood clot in an abdominal vein may be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer. [More]
Researchers show how a new drug speeds tissue regeneration in animal models

Researchers show how a new drug speeds tissue regeneration in animal models

The concept sounds like the stuff of science fiction: take a pill, and suddenly new tissues grow to replace damaged ones. Researchers at Case Western Reserve and UT Southwestern Medical Center this week announced that they have taken significant steps toward turning this once-improbable idea into a vivid reality. [More]
Advertisement